Aveanna Healthcare Issues 2026 Revenue Guidance of $2.56B-$2.58B
AVAH sits 91% above its 52-week low of $3.73 on elevated volume (2.9× avg).
Summary
Aveanna Healthcare has provided its 2026 revenue guidance, projecting figures between $2.56 billion and $2.58 billion. This forward-looking financial outlook is a critical data point for investors, offering insight into the company's expected performance and growth trajectory. This guidance is likely part of the broader financial update, which includes the strong first-quarter results mentioned in the 8-K filed concurrently. Professional traders will integrate these projections into their valuation models and assess the company's future prospects, making this a significant piece of information for investment decisions.
At the time of this announcement, AVAH was trading at $7.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $3.73 to $10.32. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.